Soufflé Therapeutics Raised $135 Million in Series B

The Boston-based biotech firm will use the funding to advance three lead clinical programs.

Updated on Oct. 13, 2026 in Biotech

Bold flat-color editorial illustration of a laboratory vial and centrifuge, representing biotech funding and pharmaceutical research development. — Soufflé Therapeutics raised $135 million in a Series B funding round to advance clinical programs for muscular dystrophy and metabolic disorders. AI Illustration. Upload story photo >

Live Poll

Do you trust that venture capital investment in new biotechnology companies accelerates effective patient medical treatments?

Soufflé Therapeutics closed an oversubscribed $135 million Series B financing round led by Juvia Group. The company intends to utilize the capital to support clinical studies for facioscapulohumeral muscular dystrophy, heart failure, and metabolic disorders.

Why it matters

The infusion of capital allows Soufflé to progress its lead programs into human clinical trials. This move validates the company's proprietary technology for targeted medical therapies beyond standard delivery methods.

The firm leverages a proprietary engine called REMEDY to facilitate cell-specific delivery of oligonucleotide therapies. This technology is designed to enable targeted drug distribution to tissues and cell types outside of the liver.

The players

Soufflé Therapeutics

A Boston-based biotechnology company focused on developing targeted oligonucleotide therapies for various medical conditions.

Juvia Group

An investment firm that acted as the lead participant in the latest funding round for Soufflé Therapeutics.

The details

Soufflé Therapeutics identifies internalizing receptors to create proprietary binders that achieve tissue-specific delivery. The company plans to expand this pipeline into a broader range of cell types and tissues following the successful financing round.

October 13, 2026: Soufflé Therapeutics announced the closing of its Series B financing round.

The Tech Race

The development of the REMEDY engine reflects a broader shift in the biotech industry toward solving the challenge of targeted drug delivery. By moving beyond the liver, Soufflé positions itself to compete with other platforms seeking precision in genetic and metabolic disease treatment.

For patients suffering from conditions like facioscapulohumeral muscular dystrophy, this funding accelerates the path toward potential clinical treatment options. The company's success indicates a potential increase in clinical trial activity within the Boston biotech ecosystem.

The takeaway

Advancements in targeted drug delivery systems remain a critical hurdle for treating complex metabolic and muscular disorders. Investors are increasingly prioritizing platforms that can demonstrate cell-specific delivery capabilities over traditional systemic treatments.